MELANOMA BRIDGE 2012, December 2nd - 4th 2012

December 2nd 2012

Chair: Nicola Mozzillo and Franco Marincola

17:00 - 17:10 Opening Ceremony
17:10 - 17:30 La storia del melanoma in Italia raccontata da Pino Cascinelli
Natale Cascinelli
17:30 - 17:50 State of the Art in target therapy for melanoma
Paolo A. Ascierto
17:50 - 10:00 L'esperienza dei pazienti
Francesco Brancaccio
, Responsabile Area Pazienti Fondazione Melanoma Onlus
18:00 - 18:10 Melanoma & Research
Valerie Guild, President of the AIM at Melanoma Foundation
18:10 - 19:30 Tavola Rotonda: Esperti e pazienti
Stefano Caldoro*, Presidente Regione Campania
Francesco De Lorenzo, Presidente FAVO
Luigi De Magistris*, Sindaco di Napoli
Michele Maio, Presidente Eletto NIBIT, Network Italiano per la Bioterapia dei Tumori
Giuseppe Palmieri, Segretario IMI, Intergruppo Melanoma Italiano, Presidente Humana Onlus
Carmine Pinto, Segretario Nazionale AIOM, Associazione Italiana di Oncologia Medica
19:30 - 20:00 Award Ceremony
The Melanoma Foundation Honorary Lecture on Melanoma Research and Treatment
20:00 - 20:30 Welcome Cocktail
20:30 Congress Official Dinner


* invited to participate


December 3rd 2012
9:00 - 09:30 Saluto delle AutoritÓ
Tonino Pedicini, Direttore Generale INT Pascale Napoli
Gennaro Ciliberto, Direttore Scientifico INT Pascale Napoli
Gaetano Lombardi, Presidente CIV INT Pascale Napoli
Nicola Mozzillo, Presidente Melanoma Bridge 2012
Francesco Marincola, Presidente Melanoma Bridge 2012
Paolo A. Ascierto, Presidente Melanoma Bridge 2012

MOLECULAR ADVANCES and BIOMARKERS


Chair: Magdalena Thurin and Franco Marincola

9:30 - 10:00 Mage-A3 Antigen Specific Immunotherapy: spontaneous and induced immune response
Vincent Brichard
10:00 - 10:30 Cancer/antigen expression and correlations with immune responses and clinical events
Sacha Gnjatic
10:30 - 11:00 The melanoma tumor microenvironment: biomarkers to biology
Thomas F. Gajewski
11:00 - 11:30 Biomarkers predicting response to immunotherapy
Helen Gogas
11:30 - 11:45 Coffee Break
11:45 - 12:15 Single Cell Network Profiling (SCNP): technology and its application to the development of cancer immunotherapy
Alessandra Cesano
12:15 - 12:45 New Markers of Melanoma Metastasis
Mohamed Kashani Sabet
12:45 - 13:15 How melanoma escapes from MAPK inhibition
Roger Lo
13:15 - 14:15 Lunch


COMBINATION THERAPIES


Chair: Paolo A. Ascierto and Nicola Mozzillo

14:50 - 15:20 Current and Future Options Adjuvant Therapy of Melanoma
John Kirkwood
15:20 - 15:50 Combinatorial Immunotherapeutic strategies
Soldano Ferrone
15:50 - 16:20 BRAFV600E targeted therapy and adoptive cell transfer immunotherapy
Nicolas Acquavella
16:20 - 16:50 Oncolytic Viral Therapy for the Treatment of Melanoma
Howard Kaufman
16:50 - 17:00 Coffee Break
17:00 - 17:30 Drug development in the era of molecular medicine: lessons from BRAF inhibitors in melanoma
Igor Puzanov
17:30 - 18:00 Effects of paradoxical activation of the MAPK pathway with BRAF inhibitors
Antoni Ribas
18:00 - 18:30 Strategies to overcome BRAF inhibitor resistance with combination therapy
Jeff Sosman
18:30 - 19:00 Novel Molecular Targets in Melanoma
Grant McArthur
19:00 - 19:15 Closing remarks



December 4th 2012

NOVEL CONCEPT


Chair: Giuseppe Palmieri and Nicola Normanno

9:20 - 09:50 Fondazione Melanoma award lecture: Inflammation and the commensal   flora affect the tumor microenvironment and the response to therapy  
Giorgio Trinchieri
9:50 - 10:20 Immuno-stromal modulation: the balance can tip either way  
Lex Eggermont
10:20 - 10:50 Intratumour Heterogeneity: is it relevant?
James Larkin
10:50 - 11:20 Brain metastases in the era of molecularly targeted and immunomodulatory therapies
Kim Margolin
11:20 - 11:30 Phase III, Randomized, Open-Label, Multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM)
Michele Del Vecchio
11:30 - 11:45 Coffee Break
11:45 - 12:00 The complexity of tumor biology challenge immune responsiveness
Ena Wang
12:00 - 12:15 Diversity and avidity: frequently neglected, yet key parameters of the anti-tumor T cell response
Paul V. Lehmann
12:15 - 12:45 Evaluation of therapeutic strategies in a genetically engineered mouse model for melanoma
Rienk Offringa
12:45 - 13:10 Technological development, research and melanoma treatment:   introperative 3D-Spect, dendritic cells and elettrochemotherapy
Lorenzo Borgognoni
13:10 - 13:30 Chemosaturation Therapy: Creating New Options in the Management of Patients with Liver Dominant Disease
Mark Faries
13:30 - 14:15 Lunch


BRIDGE BETWEEN MELANOMA AND COLO-RECTAL CANCER: BIOLOGY OF TUMOR MICROENVIRONMENT


Chair: Fernando Vidal-Vanaclocha and Gennaro Ciliberto

14:30 - 15:00 Selective biomarkers and immune modulatory molecules as targets for (immune) therapies of melanoma
Barbara Seliger
15:00 - 15:30: Effects of pH regulation on melanoma immunity
Licia Rivoltini
15:30 - 16:00 Cancer related Inflammation in tumor progression
Alberto Mantovani
16:00 - 16:30 Vaccine strategy targeting antigens expressed by tumors in their microenvironment
Bernard A. Fox
16:30 - 16:45 Coffee Break
16:45 - 17:15 Optimization of synthetic therapeutic vaccines for viral and non-viral cancer
Cornelis Melief
17:15 - 17:45 The MESOT-TREM Study: anti-CTLA-4 treatment of chemotherapy-resistant mesothelioma patients.
Luana Calabrò
17:45 - 18:15 The hepatic metastasis microenvironment for melanoma and colon cancer cells
Fernando Vidal-Vanaclocha
18:15 – 18:45 A new approach for the classification of cancer in the era of immunotherapy
JÚrome Galon
18:45 - 19:00 Closing remarks



For information please contact info@melanomabridge.org